Bio-Techne Co. (NASDAQ:TECH) Forecasted to Post FY2026 Earnings of $2.69 Per Share

Bio-Techne Co. (NASDAQ:TECH) – Research analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for Bio-Techne in a report issued on Wednesday, September 6th. Leerink Partnrs analyst P. Souda expects that the biotechnology company will earn $2.69 per share for the year. The consensus estimate for Bio-Techne’s current full-year earnings is $1.80 per share.

Several other equities analysts also recently weighed in on TECH. Benchmark restated a “buy” rating and set a $120.00 target price on shares of Bio-Techne in a report on Friday, August 18th. Robert W. Baird lowered their price objective on shares of Bio-Techne from $100.00 to $90.00 in a research note on Wednesday, August 9th. William Blair assumed coverage on shares of Bio-Techne in a report on Monday, August 28th. They issued an “outperform” rating on the stock. StockNews.com upgraded Bio-Techne from a “hold” rating to a “buy” rating in a report on Monday. Finally, Stephens reaffirmed an “overweight” rating and issued a $100.00 price objective on shares of Bio-Techne in a report on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $101.78.

Bio-Techne Stock Down 2.0 %

TECH opened at $73.98 on Thursday. The stock has a market capitalization of $11.70 billion, a P/E ratio of 42.03, a P/E/G ratio of 4.10 and a beta of 1.21. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.84 and a quick ratio of 3.50. The business has a 50 day simple moving average of $81.82 and a 200-day simple moving average of $79.45. Bio-Techne has a 12 month low of $68.00 and a 12 month high of $90.63.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The firm had revenue of $301.32 million for the quarter, compared to analyst estimates of $304.71 million. Bio-Techne had a return on equity of 15.47% and a net margin of 25.10%.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Friday, August 18th were given a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend was Thursday, August 17th. Bio-Techne’s dividend payout ratio is currently 18.18%.

Insider Buying and Selling

In other Bio-Techne news, Director Roeland Nusse sold 8,939 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $80.32, for a total value of $717,980.48. Following the completion of the transaction, the director now owns 51,872 shares of the company’s stock, valued at approximately $4,166,359.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Bio-Techne news, CEO Charles R. Kummeth sold 80,000 shares of the stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $88.36, for a total transaction of $7,068,800.00. Following the sale, the chief executive officer now owns 1,258,766 shares of the company’s stock, valued at approximately $111,224,563.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Roeland Nusse sold 8,939 shares of Bio-Techne stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $80.32, for a total value of $717,980.48. Following the completion of the sale, the director now directly owns 51,872 shares of the company’s stock, valued at $4,166,359.04. The disclosure for this sale can be found here. 4.45% of the stock is currently owned by insiders.

Institutional Trading of Bio-Techne

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in Bio-Techne by 5.8% in the second quarter. BlackRock Inc. now owns 16,916,926 shares of the biotechnology company’s stock valued at $1,380,929,000 after buying an additional 922,301 shares during the period. Select Equity Group L.P. raised its holdings in Bio-Techne by 382.9% during the 4th quarter. Select Equity Group L.P. now owns 7,153,947 shares of the biotechnology company’s stock worth $592,919,000 after buying an additional 5,672,587 shares during the period. State Street Corp increased its position in shares of Bio-Techne by 2.2% during the second quarter. State Street Corp now owns 6,414,193 shares of the biotechnology company’s stock worth $523,591,000 after acquiring an additional 136,127 shares in the last quarter. Bamco Inc. NY boosted its position in shares of Bio-Techne by 286.7% during the fourth quarter. Bamco Inc. NY now owns 5,519,062 shares of the biotechnology company’s stock worth $457,420,000 after buying an additional 4,091,998 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Bio-Techne by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 4,445,265 shares of the biotechnology company’s stock valued at $1,924,978,000 after acquiring an additional 18,627 shares in the last quarter. Institutional investors own 94.64% of the company’s stock.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.